Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 17/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3921033 | 0.89 | MEN1 (0.37) | GPR84MEN1KMT2AKDM4ERECQL | |
| SCHEMBL3916601 | 0.88 | GPR84 (0.43) | GPR84MEN1KMT2AKDM4ERECQL | |
| SCHEMBL17436482 | 0.86 | GPR84 (0.54) | GPR84MEN1KMT2AKDM4ERECQL | |
| SCHEMBL13868304 | 0.84 | GPR84 (0.54) | GPR84MEN1KMT2AKDM4ERECQL | |
| SCHEMBL3929063 | 0.80 | GPR84 (0.39) | GPR84MEN1KMT2AKDM4ERECQL | |
| SCHEMBL25484967 | 0.79 | GPR84 (0.44) | GPR84MEN1KMT2AKDM4ERECQL | |
| SCHEMBL3927270 | 0.79 | MEN1 (0.37) | GPR84MEN1KMT2AKDM4ERECQL | |
| SCHEMBL22229749 | 0.79 | CYP3A4 (0.40) | GPR84MEN1KMT2AKDM4ERECQL | |
| SCHEMBL22229688 | 0.77 | GPR84 (0.38) | GPR84MEN1KMT2AKDM4ERECQL | |
| SCHEMBL29733041 | 0.76 | MEN1 (0.39) | GPR84MEN1KMT2AKDM4ERECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517828-B2 | Chiral broensted acid catalyst for asymmetric synthesis and method of asymmetric synthesis with the catalyst | TOAGOSEI CO., LTD. (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20060276329-A1 | Asymmetric synthesis catalyst based on chiral brsnsted acid and method of asymmetric synthesis with the catalyst | TOAGOSEI CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1623971-A1 | ASYMMETRIC-SYNTHESIS CATALYST BASED ON CHIRAL BROENSTED ACID AND METHOD OF ASYMMETRIC SYNTHESIS WITH THE CATALYST | TOAGOSEI CO., LTD. (JP) | 2006-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276329-A1 | Asymmetric synthesis catalyst based on chiral brsnsted acid and method of asymmetric synthesis with the catalyst | LSS, COASY, FASN | GPR84 2758/4885MEN1 169/4885KMT2A 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.